1-[(Dimethylamino)methyl]cyclopropan-1-amine | 1338494-72-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-[(Dimethylamino)methyl]cyclopropan-1-amine
• CAS: 1338494-72-6
• 化学式: C₆H₁₄N₂
• mdl: MFCD20441459
• 分子量: 114.19
• InChiKey: ROVFTSSCUXGEQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors
  申请人：BEIGENE, LTD.

  公开号：US11220506B2

  公开（公告）日：2022-01-11

  Disclosed is a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating PI3Kδ related disorders or diseases by using the compound disclosed herein.

  公开了一种式（I）化合物或其立体异构体，或其药学上可接受的盐，以及包含其的药物组合物。还公开了一种通过使用本文公开的化合物治疗 PI3Kδ 相关紊乱或疾病的方法。
• FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD.

  公开号：EP3290419B1

  公开（公告）日：2019-08-07
• INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：EP3902542A1

  公开（公告）日：2021-11-03
• IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS
  申请人：BEIGENE, LTD.

  公开号：US20200207774A1

  公开（公告）日：2020-07-02

  Disclosed is a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating PI3Kδ related disorders or diseases by using the compound disclosed herein.
• [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF<br/>[FR] INHIBITEURS DE LA KINASE DÉPENDANTE DES CYCLINES 7 ET LEURS UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2020140098A1

  公开（公告）日：2020-07-02

  The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds of the present disclosure are inhibitors of kinases (e.g., a cyclin-dependent kinase (CDK) (e.g., CDK7)). The compounds may be selective for inhibiting the activity of a kinase (e.g., CDK7) over certain other kinases (e.g., CDK2, CDK9, CDK12). Also provided are pharmaceutical compositions, kits, methods of use, and uses that involve the compounds. The compounds may be useful in inhibiting the activity of a kinase, down-regulating the transcription of MYC or MCL-l, inhibiting the growth of a cell, inducing apoptosis of a cell, treating a disease, and/or preventing a disease (e.g., proliferative disease, cystic fibrosis).